Local control and prognostic significance of transarterial treatment for limited recurrence of ovarian cancer as third-line and beyond therapy
| Autor: | Akihiko Seki, Satoru Sueyoshi, Atsushi Hori, Shinichi Hori |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Oncology medicine.medical_specialty Third-line therapy Docetaxel Neoplasm Recurrence Quality of life Surgical oncology Internal medicine Antineoplastic Combined Chemotherapy Protocols Humans Infusions Intra-Arterial Medicine Aged Retrospective Studies Ovarian Neoplasms business.industry Retrospective cohort study Hematology General Medicine Middle Aged Prognosis medicine.disease humanities Third line Quality of Life Female Taxoids Surgery Cisplatin Neoplasm Recurrence Local business Ovarian cancer medicine.drug |
| Zdroj: | International Journal of Clinical Oncology. 19:1065-1073 |
| ISSN: | 1437-7772 1341-9625 |
| DOI: | 10.1007/s10147-014-0665-7 |
| Popis: | We aimed to retrospectively evaluate the safety and efficacy of transarterial treatment for the recurrence of ovarian cancer, limited to one or two gross regions, in a palliative setting as third-line and beyond therapy.Twenty-six consecutive patients were enrolled to undergo transarterial treatment of target lesions that were life-threatening or influenced their quality of life. Transarterial infusion via each feeding artery using 20-40 mg cisplatin and 20-40 mg docetaxel per patient was repeated every 4-6 weeks. Superabsorbent polymer microspheres were added for embolization after drug infusion, especially in hepatic or pelvic treatments. Univariate and multivariate Cox's proportional hazards models were used to assess the correlations between overall survival and individual parameters.A total of 63 feeding arteries (median 2 per patient; range 1-5) were treated for 36 target sites (liver, 12; pelvis, 8; abdominal cavity, 7; lymph node, 3; other, 6) at the initial treatment. Of the 128 total sessions, the only grade 3/4 toxicity was neutropenia (3.8 %). The target lesion response rate by RECIST ver.1.1 was 50.0 % (11.5 % complete response; 38.5 % partial response). After a median follow-up of 30 months, the median overall survival was 16 months. Among 10 tumor-associated symptomatic patients, 7 showed symptom improvement. Multivariate analyses shows that the only independent prognostic factor was target lesion response (hazard ratio 18.7; 95 % CI 1.9-183.4; p = 0.01).Transarterial treatment for ovarian cancer achieves a high local response and good symptom control, and significantly contributes to survival for patients with local control after multiple relapses. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink